THE European Medicines Agency
(EMA) has published the first risk
management plan (RMP) of a newly
authorised medicine, for the public.
It deals with Neuraceq
(florbetaben), used during brain
scans in patients with memory
problems, and details what is and
is not known about the medicine’s
safety and describes the measures
taken to prevent or minimise risks.
The EMA said it would pilot
publishing such summaries
during 2014 for all newly
authorised medicines, and would
start publishing summaries for
previously authorised medicines “at
a later stage”.
This came as part of a drive
to improve information about
medicines for the general public,
the EMA said.
To read the RMP, CLICK HERE.The above article was sent to subscribers in Pharmacy Daily's issue from 13 Mar 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Mar 14
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.